BCBSMT HEDIS® 2013 COMPARISON REPORT - Managed Care

EFFECTIVENESS OF CARE MEASURES		I	BCBSMT 2011		1	BCBSMT 2012			1	BCBSMT 2013		2012 QC National	2013 QC National
	Num	Denom		Num	Denom		% change	Num	Denom		% change		
Childhood Immunization			n=71			n=51				n=31			
DTaP	59	71	83.10%	43	51	84.31%	1.46%	26	31	83.87%	-0.52%	86.50%	87.20%
Hib	66	71	92.96%	46	51	90.20%	-2.97%	30	31	96.77%	7.29%	94.10%	94.30%
IPV	68	71	95.77%	45	51	88.24%	-7.86%	30	31	96.77%	9.67%	92.40%	92.80%
PCV	61	71	85.92%	43	51	84.31%	-1.87%	27	31	87.10%	3.31%	87.00%	86.70%
НерВ	67	71	94.37%	45	51	88.24%	-6.50%	30	31	96.77%	9.67%	87.90%	89.20%
MMR	66	71	92.96%	48	51	94.12%	1.25%	29	31	93.55%	-0.61%	91.50%	91.80%
VZV	62	71	87.32%	44	51	86.27%	-1.20%	29	31	93.55%	8.44%	91.30%	91.60%
HepA^	27	71	38.03%	21	51	41.18%	8.28%	28	31	90.32%	119.34%	39.00%	65.50%
Rotavirus	44	71	61.97%	39	51	76.47%	23.40%	21	31	67.74%	-11.41%	75.10%	76.70%
Influenza	39	71	54.93%	25	51	49.02%	-10.76%	20	31	64.52%	31.61%	61.10%	63.30%
Combo-1	57	71	80.28%	41	51	80.39%	0.14%	25	31	80.65%	0.32%	na	na
Combo-2	56	71	78.87%	39	51	76.47%	-3.04%	25	31	80.65%	5.46%	78.00%	79.70%
Combo-3	53	71	74.65%	38	51	74.51%	-0.19%	25	31	80.65%	8.23%	75.70%	76.80%
Combo-4 ^	23	71	32.39%	16	51	31.37%	-3.15%	23	31	74.19%	136.51%	na	na
Combo-5	38	71	53.52%	34	51	66.67%	24.57%	18	31	58.06%	-12.91%	na	na
Combo-6	35	71	49.30%	22	51	43.14%	-12.49%	17	31	54.84%	27.12%	na	na
Combo-7 ^	20	71	28.17%	15	51	29.41%	4.40%	17	31	54.84%	86.46%	na	na
Combo-8 ^	15	71	21.13%	10	51	19.61%	-7.19%	16	31	51.61%	163.20%	na	na
Combo-9	25	71	35.21%	21	51	41.18%	16.96%	12	31	38.71%	-6.00%	na	na
Combo-10 ^	12	71	16.90%	10	51	19.61%	16.04%	11	31	35.48%	80.95%	22.90%	37.90%
Adolescent Immunizations			n=110			n=65				n=55			
Meningococcal (MCV)	53	110	48.18%	39	65	60.00%	24.53%	30	55	55.45%	-7.58%	61.90%	66.00%
Tdap/Td	93	110	84.55%	54	65	83.08%	-1.74%	44	55	80.00%	-3.71%	77.00%	79.20%
Combo-1	53	110	48.18%	38	65	58.46%	21.34%	29	55	52.73%	-9.80%	59.40%	63.70%
HPV Vaccine for Female Adolescents			na			n=28				n=31			
	na	na	na	8	28	28.57%	na	6	31	19.35%	-32.25%	na	na
Appropriate Tx for Children w/ URI			n=126			n=114				n=53			
	111	126	88.10%	93	114	81.58%	-7.40%	44	53	83.02%	1.76%	83.90%	84.00%
Appropriate Testing for Children w/ Phary	ngitis		n=107			n=116				n=52			
	81	107	75.70%	89	116	76.72%	1.35%	32	52	61.54%	-19.79%	80.20%	80.20%
Avoidance of Antibiotic Tx for													
Adults w/ Acute Bronchitis			n=122			n=70				n=66			
	24	122	19.67%	7	70	10.00%	-49.16%	11	66	16.67%	66.70%	23.50%	24.60%
Colorectal Cancer Screening			n=2105			n=601				n=1153			
	1190	2105	56.53%	303	601	50.42%	-10.81%	657	1153	56.98%	13.01%	62.40%	63.30%

EFFECTIVENESS OF CARE MEASURES		ĺ	BCBSMT 2011		ı	BCBSMT 2012			ĺ	BCBSMT 2013		2012 QC National	2013 QC National
	Num	Denom		Num	Denom		% change	Num	Denom		% change		
Breast Cancer Screening			n=1633			n=486	J. I. J.			n=865			
·	1182	1633	72.38%	328	486	67.49%	-6.76%	652	865	75.38%	11.68%	70.50%	70.30%
Cervical Cancer Screening			n=2055			n=644				n=982			
Con victar Carroon Concoming	1608	2055	78.25%	501	644	77.80%	-0.58%	766	982	78.00%	0.26%	76.50%	75.50%
Persistence of Beta Blocker													
Treatment after Heart Attack			n=7			n=2				n=5			
	6	7	85.71%	2	2	100.00%	16.67%	5	5	100.00%	0.00%	81.30%	83.90%
Cholesterol Management for Patients													
w/ Cardiovascular Conditions			n=75			n=26				n=37			
LDL-screening	70	75	93.33%	24	26	92.31%	-1.09%	35	37	94.59%	2.47%	88.10%	88.30%
LDL-C level < 130 mg/dL	66	75	88.00%	22	26	84.62%	-3.84%	32	37	86.49%	2.21%	na	na
LDL-C level < 100 mg/dL	52	75	69.33%	15	26	57.69%	-16.79%	27	37	72.97%	26.49%	59.80%	59.90%
Comprehensive Diabetes Care			n=271			n=82				n=152			
HbA1c Tested	255	271	94.10%	75	82	91.46%	-2.81%	146	152	96.05%	5.02%	90.00%	90.10%
Poor HbA1c Control >9.0% *	42	271	15.50%	17	82	20.73%	33.74%	20	152	13.16%	-36.53%	28.30%	28.50%
HbA1c < 8.0%	198	271	73.06%	57	82	69.51%	-4.86%	115	152	75.66%	8.84%	61.20%	61.30%
HbA1c < 7.0% **	98	199	49.25%	29	61	47.54%	-3.47%	56	105	53.33%	12.19%	42.20%	43.20%
Eye Exam	163	271	60.15%	50	82	60.98%	1.38%	93	152	61.18%	0.33%	56.90%	56.80%
LDL Screening	222	271	81.92%	67	82	81.71%	-0.26%	134	152	88.16%	7.89%	85.30%	85.40%
LDL Level < 130 mg/dL	177	271	65.31%	59	82	71.95%	10.17%	110	152	72.37%	0.58%	na	na
LDL Level < 100 mg/dL	123	271	45.39%	37	82	45.12%	-0.59%	78	152	51.32%	13.73%	48.10%	48.40%
Nephropathy Monitored	239	271	88.19%	75	82	91.46%	3.71%	140	152	92.11%	0.71%	83.80%	84.30%
Blood Pressure < 140/80 mmHg	134	271	49.45%	34	82	41.46%	-16.16%	71	152	46.71%	12.66%	44.20%	44.30%
Blood Pressure < 140/90 mmHg	193	271	71.22%	63	82	76.83%	7.88%	111	152	73.03%	-4.95%	65.80%	66.50%
Follow-up for Mental Illness			n=17			n=11				n=14			
7 days	13	17	76.47%	5	11	45.45%	-40.56%	6	14	42.86%	-5.70%	58.90%	57.90%
30 days	16	17	94.12%	9	11	81.82%	-13.07%	11	14	78.57%	-3.97%	76.50%	76.00%
Antidepressant Medication Management			n=66			n=50				n=38			
Effective Acute Phase Tx	41	66	62.12%	33	50	66.00%	6.25%	27	38	71.05%	7.66%	65.60%	69.10%
Effective Continuation Phase TX	31	66	46.97%	23	50	46.00%	-2.07%	21	38	55.26%	20.14%	49.40%	53.60%
Follow-Up for Children Prescribed													
ADHD Medication			n=21			n=9				n=20			
Initiation Phase Visit	5	21	23.81%	5	9	55.56%	133.35%	4	20	20.00%	-64.00%	39.40%	38.60%
Use of Appropriate Medications													
for People with Asthma***			n=78			n=26				n=68			
Ages 5-11	10	10	100.00%	3	4	75.00%	-25.00%	2	3	66.67%	-11.11%	96.00%	95.50%
Ages 12-18	13	13	100.00%	1	1	100.00%	0.00%	2	4	50.00%	-50.00%	92.70%	92.20%
Ages 19-50	51	55	92.73%	11	12	91.67%	-1.14%	12	23	52.17%	-43.09%	89.10%	88.20%

EFFECTIVENESS OF CARE MEASURES		ı	BCBSMT 2011		1	BCBSMT 2012			,	BCBSMT 2013		2012 QC National	2013 QC National
	Num	Denom		Num	Denom		% change	Num	Denom		% change		
Ages 51-64	na	na	na	8	9	88.89%	na	15	19	78.95%	-11.19%	93.20%	92.40%
Combined ***	74	78	94.87%	23	26	88.46%	-6.76%	31	49	63.27%	-28.48%	91.90%	91.20%
Use of Spirometry in the Assessment													
& Diagnoses of COPD			n=27			n=25				n=29			
	7	27	25.93%	10	25	40.00%	54.26%	17	29	58.62%	46.55%	42.90%	43.50%
Pharmacotherapy Management of													
COPD Exacerbation			n=4			<i>n</i> =6				n=2			
Bronchodilator	4	4	100.00%	5	6	83.33%	-16.67%	2	2	100.00%	20.00%	79.90%	80.80%
Systemic Corticosteroid	4	4	100.00%	5	6	83.33%	-16.67%	2	2	100.00%	20.00%	71.30%	73.50%
Chlamydia Screening			n=315			n=98				n=135			
Ages 16-20	57	141	40.43%	14	41	34.15%	-15.53%	17	57	29.82%	-12.67%	41.50%	41.10%
Ages 21-24	65	174	37.36%	22	57	38.60%	3.32%	33	78	42.31%	9.61%	48.40%	49.20%
Combined	122	315	38.73%	36	98	36.73%	-5.16%	50	135	37.04%	0.84%	45.00%	45.10%
Use of Imaging Studies for													
Low Back Pain			n=74			n=78				n=78			
	62	74	86.78%	59	78	75.64%	-12.84%	58	69	84.06%	11.13%	74.40%	75.30%
DMARD Therapy in Rheumatoid Arthritis			n=31			n=9				n=17			
	30	31	96.77%	8	9	88.89%	-8.14%	15	17	88.24%	-0.74%	87.60%	87.90%
Annual Monitoring for Patients													
on Persistent Medications			n=1066			n=321				n=591			
ACE/ARB	461	581	79.35%	146	176	82.95%	4.54%	286	336	85.12%	2.61%	82.50%	82.90%
Anticonvulsant	15	25	60.00%	5	8	62.50%	4.17%	6	8	75.00%	20.00%	60.50%	58.80%
Digoxin	15	16	93.75%	4	4	100.00%	6.67%	13	14	92.86%	-7.14%	85.40%	86.50%
Diuretic	355	444	79.95%	108	133	81.20%	1.56%	198	233	84.98%	4.65%	82.10%	82.50%
Combined	846	1066	79.36%	263	321	81.93%	3.24%	503	591	85.11%	3.88%	81.90%	82.30%

^{*} Note: For this numerator, a lower rate indicates better performance.

BCBSMT 2011 rates based on 2010 data.

BCBSMT 2012 rates based on 2011 data.

BCBSMT 2013 rates based on 2012 data.

The 2013QC (Quality Compass®) rate comparisons are from NCQA's State of Health Care Quality 2013 Report and reflect 2012 data.

The 2012 QC (Quality Compass®) rate comparisons are from NCQA's State of Health Care Quality 2012 Report and reflect 2011 data.

^{**} Note: The HbAb1c < 7.0% denominator excludes members w/ certain conditions. Please see measure description for a list of conditions.

^{***} Note: The combined age range for this measure changed from 5-50 years in 2011 to 5-64 years in 2012 & 2013.

[^]The NCQA qualifying dosing requirements for the Hepatis A immunizations series changed from 2 doses in 2011 & 2012 to 1 dose in 2013.